CommercialCoverageMedium impact
08.01.60g, Sacituzumab govitecan-hziy (Trodelvy™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy for Sacituzumab govitecan-hziy (Trodelvy™) has updated medical necessity criteria and medical coding requirements. This affects billing and coverage determination for this oncology medication used primarily in cancer treatment.
Action Required
By July 28, 2025: Billing team and providers must review updated medical necessity criteria for Trodelvy™ (Sacituzumab govitecan-hziy) and ensure documentation meets new requirements. Update prior authorization processes and coding practices according to revised policy guidelines. Access full policy details at the source URL to understand specific documentation and coding changes.